NeXtGen Biologics

NeXtGen Biologics

Growth Stage

Patented, FDA Cleared, Novel Wound-Care Technology. New Skin In The Game!

Patented, FDA Cleared, Novel Wound-Care Technology. New Skin In The Game!

Overview

Raised this Round: Raised: $241,610

Total Commitments ($USD)

Platform

Republic

Start Date

09/01/2022

Close Date

02/28/2023

Min. Goal
$25,000
Max. Goal
$5,000,000
Min. Investment

$250

Security Type

SAFE

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

$40,000,000

Discount

0%

Year Founded

2014

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

High

Capital Intensity

High

Location

Alachua, Florida

Business Type

High Growth

NeXtGen Biologics, with a valuation of $40 million, is raising funds on Republic. The company has developed a patented and FDA-cleared wound-care technology involving the extracellular matrix (ECM). The technology captures the regenerative power of the axolotl and has potential applications in general surgery, wounds and burns, plastic surgery, cardiovascular diseases, ophthalmology, and gastrointestinal diseases. The first product of NeXtGen Biologics, NEOMATRIX, is the first ECM product derived from the axolotl and available to physicians and patients. Jonelle Toothman founded NeXtGen Biologics in April 2014. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $5 million. The campaign proceeds will be used for the soft and full-scale launch of NEOMATRIX.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$-110,221

$51,772

 

 

Net Income

$-2,007,144

$-790,983

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$337,233

$516,897

Accounts Receivable

$0

$0

Total Assets

$1,547,848

$2,069,171

Short-Term Debt

$9,761,500

$9,110,917

Long-Term Debt

$0

$155,400

Total Liabilities

$9,761,500

$9,266,317

Financials as of: 09/01/2022
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
NeXtGen Biologics on Republic 2022
Platform: Republic
Security Type: SAFE
Valuation: $40,000,000

Follow company

Follow NeXtGen Biologics on Republic 2022

Buy NeXtGen Biologics's Deal Report

Warning: according to the close date for this deal, NeXtGen Biologics may no longer be accepting investments.

NeXtGen Biologics Deal Report

Get KingsCrowd’s comprehensive report on NeXtGen Biologics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether NeXtGen Biologics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the NeXtGen Biologics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge